Therapy insight: Congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 2, 2005, Pages 95-100

  Iaina, Adrian ^a   Silverberg, Donald S ^a   Wexler, Dov ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Chronic kidney disease; Congestive heart failure; Erythropoietin; Iron

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FUROSEMIDE; IRON; PLACEBO;

ANEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FUNCTIONAL ASSESSMENT; HEART FUNCTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MORTALITY; NONHUMAN; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT;

ANEMIA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

EID: 20344390799     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0094     Document Type: Review

References (55)

1. Silveberg DS et al. (2003) The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutanous erythropoietin and intravenous iron: a randomized controlled study. Nephrol Dial Transplant 18: 141-146
2. Silverberg DS et al. (2003) Erythropoietin should be part of congestive heart failure management. Kidney Int 64 (Suppl 87): S40-S47
3. Avorn J et al. (2002) Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 162: 2002-2006
4. Perry HM Jr et al. (1995) Eearly predictors of 15 year end-stage renal disease in hypertensive patients. Hypertension 25: 587-594
5. Hillege HL et al. (2003). Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur J Heart Failure 24: 412-420
6. Knight EL et al. (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138: 849-855
7. Fine LG et al. (2000) Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 57 (Suppl 75): S22-S26
8. Ljungman S et al. (1990) Role of Kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39 (Suppl 4): 10-21
9. Dries DL et al. (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689
10. Zoccali C et al. (2003) Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 63 (Suppl 85): S105-S110
11. Silverberg DS et al. (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severre, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737-1744
12. National Kidney Foundation (2001) K/DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30 (Suppl 3): S192-S240
13. Locatelli F et al. (2004) Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (Suppl 2): S1-47
14. Packer M et al. (1999) Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 83: 1A-38A
15. Hunt SA et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 104: 2996-2300
16. Tan WHW et al. (2003) Anemia in ambulatory patients with chronic heart failure: A single-center clinical experience derived from electronic medical records. J Am Coll Cardiol 41 (Suppl A): 1039-1061A
17. Wexler D et al. (2004) Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure. Int J Cardiol 96: 79-87
18. Kosiborod M et al. (2003) The prognostic importance of anemia in patients with heart failure. Am J Med 114: 112-119
19. Tanner H et al. (2002) The prevalence of anemia in chronic heart failure. Int J Cardiol 86: 115-121
20. Al-Ahmad A et al. (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955-962
21. Cowie MR et al. (1997) The epidemiology of heart failure. Eur Heart J 18: 208-225
22. Collins AJ (2002) Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int 61 (Suppl 80): 44-48
23. Wu WC et al. (2001) Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345: 1230-1236
24. Langston RD et al. (2003) Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int 64: 1398-1405
25. Reinecke H et al. (2003) Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 24: 2142-2150
26. McKechnie RS et al. (2004) Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 110: 271-277
27. Gurm HS et al. (2004) Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 94: 30-34
28. Keane WF et al. (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int 63: 1499-1550
29. Levin A (2002) The relationship of hemoglobin level and survival: direct of indirect effects. Nephrol Dial Transplant 17 (Suppl 5): 8-13
30. Gouva C et al. (2004) Treating anemia early in renal failure slows the decline of renal function: a randomized controlled study. Kidney Int 66: 753-760
31. Anand IS et al. (1999) Pathogenesis of edema in chronic anemia: studies of body water ad sodium, renal function, hemodynamics and plasma hormones. Br Heart J 70: 357-362
32. Grune T et al. (2000) Oxidative stress in anemia. Clin Nephrol 53 (Suppl 1): S18-22
33. Hebert PC et al. (2004) Physiologic aspects of anemia. Crit Care Clinics 20: 187-212
34. Kobayashi H et al. (1989) Circulatory effects of acute normovalemic haemodilution in rats with acute myocardial infarction. Cardiovasc Res 23: 842-851
35. Tong EM and Nissenson AR (2001) Erythropoietin and anemia. Semin Nephrol 21: 190-203
36. Iverson PO et al. (2002) Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282: R116-172
37. Herrera-Garza EH et al. (1999) Tumor necrosis factor alpha. A mediator of disease progression in the failing human heart. Chest 115: 1170-1174
38. Means RT (1999) Advances in the anemia of chronic disease. Int J Hematol 70: 7-12
39. Matsouka C et al. (2004) Etiology of anemia in congestive heart failure. Eur J Heart Fail 6 (Suppl): 342A
40. Schustack A et al. (1985) Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis: a follow up of 8 years on 16 patients. Clin Nephrol 23: 303-306
41. Vaziri ND (2001) Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 38: 1-8
42. Kooistra MP et al. (1998) Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation ad aluminum. Nephrol Dial Transplant 13: 82-88
43. Silverberg DS et al. (2001) The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 55: 212-219
44. Androne AS et al. (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107: 226-229
45. Macdougall IC (1999) The role of ACE inhibitors and angiotensn II receptor blockers in the response to erythropoietin. Nephrol Dial Transplant 14: 1836-1841
46. Thomas MC et al. (2003) Unrecognized anemia in patients with diabetes. Diabetes Care 26: 1164-1169
47. Bosman DR et al. (2001) Anemia with erythropoietin deficiency occures early in diabetic nephropathy. Diabetes Care 24: 495-499
48. Silverberg DS et al. (2001) The effect of correction of mild anemia in severe resistant heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775-1780
49. Mancini DM et al. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294-299
50. Novak B et al. (2003) Anemia management in an outpatient heart failure center [abstract 386]. J Card Fail 6 (Suppl 1)
51. Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339: 584-590
52. Lim CS et al. (2004) Iron and oxidative stress in renal insufficiency. Am J Nephrol 17: 569-575
53. Martirosyan HA et al. (2004) Differential management of cardiovascular disease in ESRD by nephrologists and cardiologist. Am J Kidney Dis 44: 309-321
54. Calvillo L et al. (2003) Recombinant human erythropoietin protect the myocardium from ischemia-perfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci 100: 4802-4806
55. Ehrenreich H et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 8: 495-505